Карпов В.В.

Медицинский факультет Российского университета Дружбы народов, Институт аллергологии и клинической иммунологии, г. Москва, Российская Федерация

В начало... [1] [2] [3]

ЛИТЕРАТУРА

1 . Абдурахманов Д.Т., Хасаев А.Ш. Частота и клинические формы инфекции вируса гепатита С у пациентов из групп риска.// Стенд. докл. N219.Фальк симп. N92, СПб.: 1996.

2. Апросина З.Г. Хронические диффузные заболевания печени (современные тенденции). // Клин. фармакол. и терапия. 1996, 1, с. 14-19.

3. Апросина З.Г., Серов В.В. Хронические вирусные заболевания печени: пато- и морфогенез, клиническая характеристика.// Тер. архив, 1995, 5, с. 77-80.

4. Беляков В.Д., Акимкин В.Г. Частота выявления маркеров инфицирования вирусами гепатитов В и С в крови доноров.// Стенд. докл. N257. Фальк симп. N92, СПб.: 1996.

5. Горбаков В.В., Калинин А.В. Коррекция некоторых осложнений, развившихся на фоне лечения интерфероном-альфа2а больных хроническим гепатитом С.// Росс. журн. гастроэнтерол. и гепатол. 1996, 4, 208.

6. Ершов Ф.И. Интерфероны. М.: Медицина, 1994, с. 16-55.

7. Ершов Ф.И. Противовирусные средства.// Клин. фармакол. и терапия. 1995, 4, 72-75.

8. Жданов К.В., Лобзин Ю.В., Мукомолов С.Л. "Носительство" вирусов гепатита В и С у лиц молодо- го возраста.// Стенд. докл. N348. Фальк симп. N92, СПб.: 1996.

9. Ивашкин В.Т., Горбаков В.В., Васильев А.П. и др. Эффективность лечения рофероном-А больных хроническим гепатитом С.// Росс. журн. гастроэнтерол. и гепат. 1996, 4, 208.

1 0. Крель П.Е., Игнатова Т.М., Апросина З.Г. и др. Опыт лечения хронического гепатита С интерфероном-альфа2b, человеческим лейкоцитарным интерфероном и комплексом цитокинов.// Клин. фар- макол. и терапия. 1996, 1, c. 24-27.

11 . Крель П.Е., Игнатова Т.М., Серов В.В. и др. Лечение хронического вирусного гепатита интерфероном-альфа2b, человеческим лейкоцитарным интерфероном-альфа и комплексом цитокинов.// Стенд. докл. N408. Фальк симп. N92, СПб.: 1996.

1 2. Крель П.Е., Карпов В.В. Хронический вирусный гепатит С - значение определения репликации вируса. В сб.: Клинический диагноз - лабораторные основы. Под ред. В.В. Меньшикова. М.: Лабин- форм, 1997.

1 3. Крель П.Е., Кузнецов В.П., Беляев Д.Л. и др. Комплексное лечение интерферонами и цитокинами хронических заболеваний печени вирусной этиологии.// Клин. фармакол. и терапия. 1993, 2, c.50-51.

1 4. Серов В.В. Современная классификация хронических гепатитов.// Русск. мед. журнал. 1996, т. 4, 3, c. 179-183.

1 5. Хазанов А.И., Васильев А.П., Ивлев А.С. и др. К этиологии циррозов печени.// Росс. журн. гаст- роэнтерол. и гепат. 1996, т.6, 4, c. 209.

1 6. Acone N; Aquila G; Magliocca M. IFN in the treatment of chronic viral hepatitis. Efficacy and tolerance of lymphoblastoid alpha interferon in HIV-negative drug addicts and associated chronic active hepatitis C.// Clin.Ter. 1994 Nov; 145(11): 369-72.

1 7. Aiyama T et al. Changes in serum hepatitis C virus RNA titer and response to interferon therapy in patients with chronic hepatitis C.// Dig-Dis-Sci 1994 Oct.:2244-9.

1 8. Alberti A, Morsica G, Chemello L et al. Hepatitis C viraemia and liver disease in symptom-free individuals.// Lancet 1992; 340: 697-98.

1 9. Alter HJ. Chronic consequences of non-A, non-B hepatitis./ In: Current Perspectives in Hepatology. Seeff LB, Lewis JH, Plenum Publishing, New York, 1989, 83-97.

20. Alter HJ. Clinical, virological and epidemiological basis for the treatment of chronic non-A, non-B hepatitis.// Journal of Hepatology 1990; 11 (Suppl. 1): S19-S25.

21. Andreone P; Cursaro C; Gramenzi A et al. Indomethacin enhances serum 2'5'-oligoadenylate synthetase in patients with hepatitis B and C virus chronic active hepatitis.// J Hepatol; 994;21(6):984-8.

22. Angelico M; Gandin C; Pescarmona E et al. Recombinant interferon-alpha and ursodeoxycholic acid versus inter-feron-alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up.// Am J Gastroenterol. 1995 Feb; 90(2): 263-9.

23. Antonelli G, Gianelli G, Currenti M et al. Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-a2 therapy.// Clin Exp Immunol 1996; 104: 384-87.

24. Arase Y; Kumada H; Chayama K . Interferon retreatment of nonresponders with HCV-RNA-positive chronic hepatitis C.// J Gastroenterol. 1994 Jun; 29(3): 299-304.

25. Balkwill FR. Peptide regulatory factors: interferons.// Lancet 1989; i: 1060-3.

26. Balkwill FR. Cytokine amplification and inhibition of immune and inflammatory responses.// J Viral Hep, 4, Suppl 2, 1997. pp 6-15.

27. Bardelli F, Messori A, Rampazzo R et al. Effect of recombinant or lymphoblastoid interferon-alpha on alanin aminotransferase in patients with chronic hepatitis C or chronic non-A, non-B hepatitis: A meta-analysis.// Clin Drug Invest 1995; 9 (5): 239-54.

28. Bellary S; Smith DG; Bankes P .High dose interferon alpha-2b therapy for chronic hepatitis C: an open label study of the response and predictors of response.// Am J Gastroenterol. 1995; 90(2): 259-62. 29. Bhandari BN; WrightTL. Hepatitis C: an overview.// Annu Rev Med.1995; 46: 309-17.

30. Bojic I; Lilic D; Radojcic C. Deterioration of mixed cryoglobulinemia during treatment with interferon-alpha-2a.// J Gastroenterol. 1994 Jun; 29(3): 369-71.

31. Bon E; Cantagrel A; Moulinier L. [Rheumatic manifestations of chronic hepatitis C and response to the treatment with interferon alpha-2b] Manifestations rhumatologiques des hepatites C chroniques et reponse au traitement par interferon alpha-2b.// Rev Rhum Ed Fr. 1994; 61(7-8): 497-504.

32. Borden EC, Fall LA. Interferons: biological, cell growth, inhibitory, and immunological effects. Progress in Hematology 1981; 12:299-339.

33. Borrow P. Mechanisms of viral clearance and persistence.// J Viral Hep, 4, Suppl 2, 1997. 16-24.

34. Boucher E; Jouanolle H; Andre P et al. Interferon and ursodeoxycholic acid combined therapy in the treat ment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients.// Hepatology. 1995 Feb; 21(2): 322-7.

35. Bradley DW. Editorial: Prospects for a Hepatitis C Vaccine. American Liver Foundation Update (Fall 1994, http:\www\alf).

36. Bradley DW. Enterically transmitted nonA, nonB hepatitis.// Brit Med Bulletin 1990; 46: 462-80. 37. Brillanti S; Garson J; Foli M et al.A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa resistant chronic hepatitis C.// Gastroenterology. 1994 Sep; 107(3): 812-7. 38. Budillon G; Cimino L; Del Vecchio Blanco C et al. Long term follow-up evaluation in HCV chronic hepatitis treated with alpha-2b interferon. A comparison of two protocols [published erratum appears in Ital J Gastroenterol 1994, May;26(4):186;// Ital J Gastroenterol. 1994 Jan-Feb; 26(1): 16-20.

39. Camps J, Garcia-Granero M, Riezu-Boj JI et al. Prediction of the response of chronic hepatitis C to interferon alfa: A statistical analysis of pretreatment variables.// J Hepatol 1994; 21:12-17.

40. Cartabelotta A. Therapy of Chronic hepatitis C non responders to alfa-interferon: A preliminary report of intravenous natural beta-interferon. 5th UEGW, Paris, 1996, 41 1041 .

41. Causse X, Godinot H, Ouzan D et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis.// Gastroenterology 1991; 101:497-502.

42. Cesaro S; Rossetti F; De Moliner L. Interferon for chronic hepatitis C in patients cured of malignancy.// Eur J Pediatr. 1994 Sep; 153(9): 659-62.

43. Chayama K [Serial amino acid sequence change in the hypervariable region of hepatitis C virus] Nippon-Rinsho. 1994 Jul; 52(7): 1716-20.

44. Chemello L; Bonetti P; Cavalletto L . Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. The TriVeneto Viral Hepatitis Group.// Hepatology. 1995; 22(3): 700-6. 45. Choo QL, Han JH, Weiner AJ et al. Hepatitis C virus is a distant relative of the flaviviruses and pestiviruses. In: Viral hepatitis C, D and E (Proceedings of International Meeting on non-A, non-B Hepatitis, Tokyo, Japan). Elsevier, Amsterdam, 1991; p 47-52..

46. Choo QL, Kuo G et al. Isolation of cDNA fragment from a blood-borne non-A, non-B viral hepatitis agent.// Science 1989; 244: 359-62..

47. Cimino L, Nardone G, Citarella C et al. Treatment of chronic hepatitis C with recombinant interferon alfa.// Eur J Gastroenterol 1991; 23: 399-402..

48. Colombo M, Rumi MG, Marcelli R et al. Randomised controlled trial of recombinant interferon alfa in patients with chronic hepatitis C.// Hepatology 1991; 14 (4) Part II: (Abstract 101).

49. Consensus on Treatment of Chronic Hepatitis C. American Liver Foundation. Bethesda 1997.

50. Craxi A, Almasio P, Schalm S. Evaluation of antiviral therapy efficacy of CH-C. EUROHEP CONSENSUS.// J Viral Hepatitis,1996,3,273-76.

51. Craxi A, Linea C, Magrin S. Non response to interferon in chronic hepatitis B and C: features and mechanisms. In: Treatment of Chronic Viral Hepatitis, 1997.

52. Crosignani A, Budillon G, Del Vecchio Blanco et al. Taurodeoxycholic acid for the treatment of HCV-related chronic hepatitis: A multicenter, placebo-controlled study. 5-th UEGW Conference, Paris, P 25, 632.

53. Cuthbert JA. Hepatitis C: progress and problems.// Clin Microbiol Rev. 1994 Oct; 7(4): 505-32.. 54. Cuypers HT, Winkel IN, Van der Poel CL et al. Analysis of genomic variability of hepatitis C virus.// Hepatology 1991; 13: S15-S19.

55. Czaja AJ. Autoimmune hepatitis and viral infection.// Gastroenterol Clin NAm.1994;23(3):547-66. 56. Dammacco F; Sansonno D; Han JH et al. Natural interferon-alpha versus its combination with 6-methylprednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study.// Blood. 1994 Nov 15; 84(10): 3336-43.

57. David O, Pucci A, Palladin D et al. Histologic changes in liver biopsy specimens produced by recombinant interferon-alpha2b therapy for chronic HANB viral hepatitis:A randomised controlled trial. // Am J Clin Pat 1992; 98.

58. Davis GL. Interferon treatment of chronic hepatitis C.// Am J Med 1994; 96 (Suppl):41-46.

59. Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alpha: A multicenter randomised, controlled trial.// N Eng J Med 1989; 321: 1501-6.

60. Davis GL, Lindsay K, Albrecht J et al. Predictors of response to recombinant interferon treatment in patients with chronic hepatitis C.// Hepatology 1990; 12:905.

61. De Groot J. Prevalence and significance of anti-HCV antibodies.// Acta Gastroenterologica Belgica 1991; 54(3-4): 248-56.

62. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: Diagnosis, grading and staging.// Hepatology 1994; 19: 1513-20.

63. Dienes H, Hutteroth T, Hess G, Meuer S. Immunoelectron microscopic observations on the inflammatory infiltrates and HLA antigens in hepatitis B and non-A, non-B.// Hepatology 1987; 7: 1317-25.

64. Dienstag JL. Non-A, non B hepatitis II: experimental transmission, putative virus agents and markers and prevention.// Gastroenterology 1983; 85: 743-68.

65. Diodati G, Bornelli P, Scaccabrarozzi S et al. Changes of antibodies to different epitopes of HCV during interferon therapy of chronic NANB hepatitis.// Hepatology 1992;16:530.

66. Dumoulin FL; Klein P; Fischer HP. [Chronic hepatitis C in type II cryoglobulinemia and cutaneous vasculitis] Chronische Hepatitis C bei Typ II Kryoglobulinamie und kutaner Vaskulitis.// Dtsch Med Wochenschr.1994 Sep 16; 119(37): 1239-42.

67. Ebeling F, Naukkarinen R, Leikola J et al. Recombinant immunoblot assay for hepatitis C virus antibody as predictor of infectivity (letter).// Lancet 1990; 335:982-3.

68. El Shazly Y; Abdel Salam AF; Abdel Ghaffar A .Schistosomiasis as an important determining factor for the response of Egyptian patients with chronic hepatitis C to therapy with recombinant human alpha-2 interferon.// Trans R Soc Trop Med Hyg. 1994 Mar -Apr; 88(2): 229-31

69. Enomoto N; Kurosaki M; Koizumi K et al. [Fluctuation of HCV quasispecies population during interferon therapy; analysis by single strand conformation polymorphism]// Nippon Rinsho. 1994 Jul; 52(7): 1707-15.

70. Estebahn JI. Diagnostic Tests in HCV infection. In: HCV infection: Epidemiology, Diagnosis and Treatment. Supplemental Monograph 1995, Medical Communication Resources Inc., Southwestern Medical Center, Dallas, Texas, p12.

71. Estebahn JL, Genesca J, Alter HJ. Hepatitis C: Molecular biology, pathogenesis, epidemiology, clinical features and prevention./ Progress in Liver Diseases. Chapter 12. 1996, 253-282.

72. Eyster ME; Sanders JC; Battegay M; Di Bisceglie AM .Suppression of hepatitis C virus (HCV) replication by hepatitis D virus (HDV) in HIV-infected hemophiliacs with chronic hepatitis B and C. Dig Dis Sci. 1995 Jul; 40(7): 1583-8.

73. Fagan EA, Williams R. Fulminant viral hepatitis.// British Medical Bulletin 1990; 46: 462-80.

74. Feray C; Samuel D; Gigou M at al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection.// Hepatology. 1995 Oct; 22: 1084-9.

75. Fernandez I; Castellano G; Canga F et al.[A comparative randomized controlled study of the efficacy of interferon alfa-2b and interferon alfa-2a in the treatment of chronic hepatitis C.] Gastroenterol Hepatol. 1995 Feb; 18(2): 66 72.

76. Fong TL; Valinluck B; Govindarajan S et al. Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C.// Gastroenterology 1994; 107(1): 196-9.

77. Fried MW, Hoofnagle JH, Bisceglie AM. Alpha interferon treatment for chronic hepatitis C. Viral Hepatitis Management: Standards for the future. Abstract Book, Cannes, 1992. Macclesfield, UK: Adelphi Communications Ltd. 1992; 98.

78. Fried MW; Hoofnagle JH. Therapy of hepatitis C.// Semin Liver Dis. 1995 Feb; 15(1): 82-91.

79. Gane EJ; Tibbs CJ; Ramage JK et al. Ribavirin therapy for hepatitis C infection following liver transplantation.Transpl-Int. 1995; 8(1): 61-4.

80. Gerber MA. Morpologic Studies of Hepatitis C. In: HCV infection: Epidemiology, Diagnosis and Treatment. Supplemental Monograph 1995, Medical Communication Resources Inc., Southwestern Medical Center, Dallas, Texas, pp13-14.

81. Gerken G; Teuber G; Goergen B. Interferon-alpha retreatment in chronic hepatitis C.// J Hepatol. 1995; 22(1 Suppl): 118-21.

82. Goeser T; Theilmann L .Therapy of chronic viral hepatitis.// Int J Clin Pharmacol Ther. 1994 Nov; 32(11): 57 1-6.

83. Gonzalez-Peralta RP,Davis GL, Lau JYN. Pathogenetic mechanisms of hepatocellular damage in chronic hepatitis C virus infection.// J Hepatol 1994; 21: 4-11.

84. Gordon S. Extrahepatic manifestations of hepatitis C.// Dig Dis 1996; 14:157-68.

85. Green M, Kirkwood JM. INTRON A: A Clinical Monograph. Kenilworth, NJ, Schering-Plough Corp., 1 986.

86. Greenberg H, Pollard R, Jutwick L et al. Effect of human leucocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis.// N Engl J Med 1976, 295: 517-22..

87. Hadziyannis S, Rodes J, Bruix J et al. Impact of HBV, HCV and HGV on hepatocellular carcinomas in Europe: Results of an European Concerted Action. J Hepatol. 1997; 26 (Suppl 1): 139. Abstract P/C 11/06.

88. Hagiwara H, Hayashi N, Mita E et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy.// Gastroenterology 1993;104: 877-83.

89. Hamada M; Kihira T; Takase K . Hepatocyte regeneration in chronic hepatitis C and interferon treatment: analysis of immunohistological identification of proliferating cell nuclear antigen (PCNA).// J Gastroenterol. 1995 Jun; 30(3): 372-8.

90. Han JH, Shyamala V, Richman KH et al. Characterization of the terminal regions of hepatitis C viral RNA: identification of conserved sequences in the 5' untranslated region and poly(A) tails at the 3' end. // Proc. Nat. Acad. Sc. USA 1991; 88: 1711-15.

91. Hanada H; Hino K; Fuji K. "Rebound" phenomenon of hepatitis C viremia after interferon therapy in "relapsed" patients with chronic hepatitis C.// J Gastroenterol. 1995 Jun; 30(3): 347-50.

92. Hayashi J; Kishihara Y; Tani Y. Effectiveness of relative low-dose interferon treatment for patients with chronic hepatitis C.// Fukuoka Igaku Zasshi. 1994 Jul; 85(7): 211-8.

93. Hayashi J; Ohmiya M; Kishihara Y et al. A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C.// Am J Gastroenterol. 1994 Dec; 89(12): 2151-6.

94. Higashi Y; Kakumu S [Genomic changes in the E2/NS1 region of HCV before and after IFN therapy in relation to clinical course] Nippon Rinsho. 1994 Jul; 52(7): 1721-7

95. Hoofnagle JH, Mullen KD, Jones DB et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: A preliminary report.// N Engl J Med 1986; 315:1575-78.

96. Horiike N; Masumoto T; Nakanishi K Interferon therapy for patients more than 60 years of age with chronic hepatitis C.// J Gastroenterol Hepatol. 1995 May-Jun; 10(3): 246-9.

97. Houghton M, Weiner A et al. Molecular biology of the hepatitis C viruses: implications for diagnosis and control.// Hepatology 1991; 14: 381-88.

98. Hwang SJ; Chan CY; Lu RH et al. Randomized controlled trial of recombinant interferon-alpha 2b in the treatment of Chines patients with chronic hepatitis C.// J Interferon Cytokine Res. 1995;15(7): 611-6.

99. Iino S. High dose interferon treatment of chronic hepatitis C.// Gut 1993; 34 (Suppl 2) : S43-S49.

1 00. Iino S; Hino K; Yasuda K .Current state of interferon therapy for chronic hepatitis C.// Intervirology. 1994; 37(2): 87-100.

1 01. Inoue O; Yano M.[Long-term prognosis after interferon therapy in chronic hepatitis type C] Nippon Rinsho. 1994 Jul; 52(7): 1828-31.

1 02. INTRON A: A Product Monograph. Data file. Kenilworth, NJ, Schering-Plough Corp., 1986.

1 03. Isaacs A, Lindermann J. Virus interference. 1. The Interferons. Proceedings of the Royal Society of London (Biology) 1957; 147: 258-67.

1 04. Iwabuchi S; Osada T; Takatori M et al.[Long-term interferon (IFN), neominophagen C (SNMC) combination therapy of active liver cirrhosis type C] Nippon Rinsho. 1994 Jul; 52(7): 1880-8.

1 05. Iwabuchi S; Yoshida H; Fukui S. [Study for relapse cases of chronic hepatitis C treated with interferon (IFN) and approach to more successful retreatment of IFN]. Nippon Rinsho. 1994 Jul; 52(7): 1810-6.

1 06. Johnson YN Lau , Davis GL, Kniffen J et al. Significance of serum hepatitis C RNA levels in chronic hepatitis C.// Lancet 1993; 341:1501-04.

1 07. Johnson RJ; Gretch DR; Couser WG . Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy.// Kidney Int. 1994 Dec; 46(6): 1700-4

1 08. Jouet P, Thoraval F,Dhumeaux D et al. Comparative efficacy of IFN alfain cirrhotic and non-cirrhotic patients with non-A, non-B, C hepatitis.// Gastroenterology 1994; 106: 686-90.

1 09. Kato T, Esumi M, Yamashita S et al. Interferon-inducible gene expression in chimpanzee liver infected with hepatitis C virus.// Virology 1992; 190: 856-60.

11 0. Kawano S; Tanaka M; Fujiyama S et al. Clinical usefulness of an assay for hepatitis C virus core in the diagnosis of non-A, non-B hepatitis and monitoring of the response to interferon therapy.// J Gastroenterol Hepatol. 1994 May-Jun; 9(3): 217-22..

111. Kishihara Y; Hayashi J; Ohmiya M . A preliminary study of retreatment of chronic hepatitis C with interferon.// Fukuoka Igaku Zasshi. 1995 Apr; 86(4): 113-20.

11 2. Kitamura A; Takahashi K; Okajima A et al. Induction of the human gene for p44, a hepatitis C associated microtubular aggregate protein, by interferon-alpha/beta.// Eur J Biochem. 1994 Sep 15; 224(3): 877-83.

11 3. Kiyosawa K, Akahane Y, Nagata A et al. Hepatocellular carcinoma after non-A, non-B posttransfusion hepatitis.// Am J Gastroenterol 1984; 79: 777-81.

11 4. Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis.// Hepatology 1981; 1: 431-5.

11 5. Koskinas J; Tibbs C; Saleh MG et al.Effects of ribavirin on intrahepatic and extrahepatic expression of hepatitis C virus in interferon nonresponsive patients.// J Med Virol. 1995 Jan; 45(1): 29-34.

11 6. Koziel MJ. The role of immune responses in the pathogenesis of hepatitis C virus infection.// J Viral Hep, 4, Suppl 2, 1997. pp 31-41.

11 7. Kuder P, Abergel A, Jouanel P et al. Is interferon alpha atherogenic? 5th United European Gastroenterology Week, Paris, 1996, PP0 0269.

11 8. Kumagai N; Kuramochi S. [Correlation between histological features of liver biopsy specimens and clinical effect of interferon on patients with chronic hepatitis C]. Nippon Rinsho. 1994; 52(7): 1769-73.

11 9. Kuo G et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis.// Science 1989; 244: 362-64.

1 20. Kurihara T; Abe K; Ishiguro H et al. Effect of [beta]-interferon therapy in a patient with chronic active hepatitis type C associated with interstitial pneumonia and rheumatoid arthritis: a case report.// Clin Ther. 1994 Nov-Dec; 16(6): 1028-35.

1 21. Kusaka S; Okusa T; Araki A. Prediction of relapses after interferon-alpha therapy by hepatitis C virus RNA in peripheral blood mononuclear cells.// J Med Virol. 1995 Jul; 46(3): 265-8.

1 22. Lam NP; DeGuzman LJ; Pitrak D; Layden TJ. Clinical and histologic predictors of response to interferon-alpha in patients with chronic hepatitis C viral infection.// Dig Dis Sci. 1994 Dec; 39(12): 2660-4.

1 23. Lau JYN, Davis GL, Kniffen J et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis.// Lancet 1993; 341: 1501-4.

1 24. Lebovics E; Lantin J; Chaurushia G et al. The breakthrough phenomenon during alpha-interferon therapy of chronic hepatitis C: incidence, management, and outcome.// Am J Gastroenterol. 1995 Jun; 90(6): 951-4.

1 25. Lemon SM. Targeting the Achilles' heel of hepatitis C virus.// Hepatology, 1997, 25, 1035-37.

1 26. Lenzi M, Ballardini G, Fusconi M et al. Type 2 autoimmune hepatitis and hepatitis C virus infection. // Lancet 1990; 335: 258-59.

1 27. Lohr H; Goergen B; Weber W et al. Mixed cryoglobulinemia type II in chronic hepatitis B associated with HBe-minus HBV mutant: cellular immune reactions and response to interferon treatment.// J Med Virol. 1994 Dec; 44(4): 330-5.

1 28. Louie RE; Galloway CJ; Dumas ML et al. Inactivation of hepatitis C virus in low pH intravenous immunoglobulin.// S Biologicals. 1994 Mar; 22(1): 13-9.

1 29. Maeda T; Onishi S; Miura T. Exacerbation of primary biliary cirrhosis during interferon-alpha 2b therapy for chronic active hepatitis C.// Dig Dis Sci. 1995 Jun; 40(6): 1226-30.

1 30. Magrin S, Craxi G, Fiorentino C et al. Is autoimmune chronic active hepatitis an HCV-related disease? // Journal of Hepatology 1991; 13:56-60.

1 31. Maier KP. Hepatitis C: Klinik, Verlauf und Therapie.// Schweiz Rundsch Med Prax. 1994; 83(36): 1 005-7.

1 32. Malaguarnera P, Restuccia S, Trovato G et al. Interferon-alpha treatment inpatients with chronic hepatitis C: A meta-analytic evaluation.// Clin Drug Invest 1995; 9:141-9.

1 33. Malaguarnera M. An increased cardiac risk during IFN treatment.// Hepatology 1995; A 50.

1 34. Manns MP, Obermayer-Straub P. Viral induction of autoimmunity: mechanisms and examples in hepatology.// J Viral Hep, 4, Suppl 2, 1997. pp 42-47.

1 35. Marcellin P,Boyer N, Giostra O et al. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicente randomised controlled trial from France.// Hepatology 1991; 13:393-7.

1 36. Marcellin P; Boyer N; Degott C et al Long-term histologic and viral changes in patients with chronic hepatitis C who responded to alpha interferon.// Liver. 1994 Dec; 14(6): 302-7.

1 37. Marcellin P; Pouteau M; Martinot-Peignoux M. Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C.// Gastroenterology. 1995 Jul; 109(1): 156-6.

1 38. Matsuda J; Saitoh N; Gotoh M et al. High prevalence of antiphospholipid antibodies and anti-thyroglobulin antibody in patients with hepatitis C virus infection treated with interferon-alpha. Am J Gastroenterol. 1995 Jul; 90(7): 1138-41.

1 39. Matsuda Y. [Effects of interferon treatment in alcoholic liver injury].// Nippon Rinsho. 1994 Jul; 52(7): 1 869-74.

1 40. Mattson L, Grillner L, Weiland O. Seroconversion to hepatitis C virus antibodies in patients with acute posttranfusion hepatitis non-A, non-B in Sweden with a second generation test.// Scand J Infect Dis 1992; 24:15-20.

1 41. Mattson L, Sonnerborg A, Weiland O. Clinical outcome and reactivity to hepatitis C virus antigen correlated to hepatitis C viraemia: a 13-year follow-up study.// Liver 1993; 13:274-78.

1 42. Maynard M et al. Interferon therapy combined with nonsteroid antiinflammatory drugs does not induce a significant increase of 2'5' oligoadenylate synthetase activity in patients with CH-C./ 5th UEGW, Paris, 1996, P 25 0637.

1 43. Mazzaro C; Pozzato G; Moretti M . Long-term effects of alpha-interferon therapy for type II mixed cryoglobulinemia [published erratum appears in Haematologica 1994 Sep-Oct; 486]// Haematologica. 1994 Jul-Aug; 79(4): 342-9.

1 44. McDonnell WM, Askari FK. DNA Vaccines.// N Engl J Med 1996, 334, 1:42-45.

1 45. McIntyre N. Clinical presentation of acute viral hepatitis. Brit Med Bulletin 1990; 46: 533-47.

1 46. Miller RH, Purcell RH. Hepatitis C virus shares amino acids with pestiviruses and flaviviruses as well as members of two plant virus supergroups.// Proc Nat Acad Sci; 1990; 87: 2057-61.

1 47. Minohara Y; Kato T; Kanki K et al. Relation between serum hepatitis C virus RNA levels and efficacy of interferon-beta therapy.// Acta Paediatr Jpn. 1995 Aug; 37(4): 530-3.

1 48. Muratori L; Giostra F; Cataleta M. Testing for hepatitis C virus sequences in peripheral blood mononuc lear cells of patients with chronic hepatitis C in the absence of serum hepatitis C virus RNA [published erratum appears in Liver 1995 Apr;:111].// Liver. 1994 Jun; 14(3): 124-8.

1 49. Muratori L; Lenzi M; Cataleta M et al. Interferon therapy in liver/kidney microsomal antibody type 1 positive patients with chronic hepatitis C.// J Hepatol. 1994 Aug; 21(2): 199-203.

1 50. Nadir A; Smith JW; Matter B . Type 2 cryoglobulinemia and hepatitis C virus: its recognition and treatment.// J Okla State Med Assoc. 1994 Oct; 87(10): 449-53.

1 51. Nagabushan TL, Surprenant H, Le HV et al. Characterization of genetically engineered alpha-2 interferon, in Zoon KC, Noguchi PD, Liu TY (eds):/ Interferon research, Clinical applications and regulatory considerations. NY, Elsevier, 1984.

1 52. Nakazawa T; Kato N; Ohkoshi S; Shibuya A; Shimotohno K. Characterization of the 5' noncoding and structural region of the hepatitis C virus genome from patients with non-A, non-B hepatitis responding differently to interferon treatment. [Interferon or C virus-induced autoimmune chronic hepatitis? Report of personal observations and review of the literature]// J Hepatol. 1994; 20(5): 623-9.

1 53. Ngatchu T, Stroffolini T, Rapicetta M. Seroprevalence of anti-HCV in an urban chield population: a pilot survey in a developing area, Cameroon.// J Tropic Med and Hyg 1992; 95(1): 57-61.

1 54. Nishiguchi S, Kuroki T, Nakatani S et al. Randomised trial of effects of interferon-alfa on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.// Lancet 1995; 346: 1051-55.

1 55. Okamoto H, Kurai K, Okada S I et al. Full-length sequence of a hepatitis C virus genome having poor homology to reported isolates: comparative study of four distinctive genotypes.// Virology 1992; 188:331-41.

1 56. Okazaki T; Yoshihara H; Suzuki K. Efficacy of interferon therapy in patients with chronic hepatitis Comparison between non-drinkers and drinkers.// Scand J Gastroenterol. 1994 Nov; 29(11): 1039-43.

1 57. Okuno T; Arai K; Shindo M.[Efficacy of interferon combined glycyrrhizin therapy in patients with chronic hepatitis C resistant to interferon therapy]// Nippon-Rinsho. 1994 Jul; 52(7): 1823-7.

1 58. Onitsuka A; Yasuda H; Yamada N; Miyata T; Kachi T.[A case of ruptured hepatocellular carcinoma with rapid growth after the interferon therapy in chronic hepatitis].// Nippon Geka Gakkai Zasshi. 1994 Nov; 95(11): 838-42.

1 59. Ounanian A; Gueddah N; Rolachon A. Hepatitis C virus RNA in plasma and blood mononuclear cells in patients with chronic hepatitis C treated with alpha-interferon.// J Med Virol. 1995;45(2): 141-5.

1 60. Pappas SC, Hoofnagle JH, Young N et al. Treatment of chronic non-A, non-B hepatitis with acyclovir: pilot study.// J Med Virol 1985; 15:1-9.

1 61. Pardo M; Castillo I; Navas S; Carreno V. Treatment of chronic hepatitis C with cirrhosis with recombinant human granulocyte colony-stimulating factor plus recombinant interferon-alpha.// J Med Virol. 1995 Apr; 45(4): 439-44.

1 62. Pateron D; Hartmann DJ; Ducclos-Vallee JC et al. Latent autoimmune disease in patients with chronic HCV hepatitis.// J.Hepatol., 1992, 16:244-5.

1 63. Peano G; Menardi G; Ponzetto A et al. HLA-DR5 antigen. A genetic factor influencing the outcome of hepatitis C infection?.// Arch Int Med.1994 Dec 12-26, 154(23):2733-6.

1 64. Peerlinck K; Willems M; Sheng L. Rapid clearance of hepatitis C virus RNA in peripheral blood mononuclear cells of patients with clotting disorders and chronic hepatitis C treated with alpha-2b interferon is not a predictor for sustained response to treatment.// Br J Haematol 1994; 86(4): 816-9.

1 65. Pereira LM; Melo MC; Saleh MG. Hepatitis C virus infection in Schistosomiasis mansoni in Brazil.// J Med Virol. 1995 Apr; 45(4): 423-8.

1 66. Perez R; Pravia R; Linares A et al. Response related factors in recombinant interferon-alpha2b treatment of chronic hepatitis C.// Gut 1993; 34 (Suppl):S 139-40.

1 67. Perillo RP. Antiviral agents in the treatment of chronic viral hepatitis./ Progress in Liver Diseases. Chapter 13. 1996, 283-309.

1 68. Piazza M; Orlando R; Tosone G et al. Treatment of chronic hepatitis C with recombinant interferon alfa-2b.// Gut 1993; 34 (Suppl 2): S128-S129.

1 69. Picciotto A; Callea F; Varagona G .Lymphoblastoid interferon therapy in chronic hepatitis C: biochemical, virological and histological evaluation of two different doses.// Liver. 1995; 15(1): 20-4.

1 70. Pol S; Thiers V; Carnot F; Zins B. Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodialyzed patients.// Kidney Int. 1995 May; 47(5): 1412-8.

1 71. Poynard T. Multicenter Study Group. A randomised clinical of 18 months therapy with alpha2b interferon (IFN 2b) in patients with chronic hepatitis C.// J Hepatol 1993; 18 (Suppl 1): S 52.

1 72. Poynard T; Bedossa P; Chevallier M. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group CM: Comment:// N Engl J Med 1995 Jun 1;332(22):1457-62..

1 73. Preziati D; La Rosa L; Covini G et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a.// Eur J Endocrinol 1995 May; 132(5): 587-93.

1 74. Puoti C; Magrini A; Filippi T et al. Effects of ursodeoxycholic acid on serum liver enzymes in patients with hepatitis C virus-related chronic liver disease.Eur J Gastroenterol Hepatol 1995 Feb; 7(2): 151-4.

1 75. Reichard O; Glaumann H; Fryden A et al. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment.// Hepatology 1995 Apr; 21(4): 918-22.

1 76. Reichard O; Glaumann H; Norkrans G . Histological outcome in patients with chronic hepatitis C given a 60-week interferon alfa-2b treatment course.// Liver. 1994 Aug; 14(4): 169-74.

1 77. Revel M, Chabath J. Interferon-activated genes. Trends in Biochem Science 1986; 11: 166-70.

1 78. Roffi L; Mels GC; Antonelli G et al Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: prevalence, etiology, and management.// Hepatology 1995, 21(3): 645-9.

1 79. Roggendorf M et al. Antibodies to hepatitis C virus (Letter).// Lancet 1989; 2: 324-25.

180. Roithinger FX; Allinger S; Kirchgatterer A. A lethal course of chronic hepatitis C, glomerulonephritis, and pulmonary vasculitis unresponsive to interferon treatment.// Am J Gastroenterol. 1995; 90(6): 1006-8.

1 81. Rostaing L; Izopet J; Baron E et al. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients.// Transplantation. 1995 May 27; 59(10): 1426-31.

1 82. Russo-Mancuso G; Di Gregorio F; Passero E . Efficacy of an analysis of lymphocyte subsets in predicting the clinical response to alpha-interferon therapy in thalassaemia patients with chronic infection by hepatitis C virus: a pilot study.// Br J Haematol. 1995 Feb; 89(2): 291-8.

1 83. Saleh MG; Tibbs CJ; Koskinas J et al. Hepatic and extrahepatic hepatitis C virus replication in relation to response to interferon therapy.// Hepatology 1994; 20: 1399-403.

1 84. Samuel CE. Mechanisms of Interferon Action. CMC Press Florida, 1987, p.111.

1 85. Sanchez JF; Pascua J; Sanchez F. [Treatment of chronic hepatitis C virus infection with interferon in patients infected with the human immunodeficiency virus]. Tratamiento con interferon de la hepatitis cronica por virus de lahepatitis C en pacientes infectados por el virus de la inmunodeficiencia humana. // An Med Interna. 1994 Dec; 11(12): 575-9.

1 86. Saracco G; Rizetto M. The results of a long-term follow-up study of patients with chronic HCV infection treated with interferon-alpha2b.// Viral Hepatitis Management: Standards for the future. Abstract Book, Cannes, 1992. Macclesfield, UK: Adelphi Comms Ltd. 1992; 90-91.

1 87. Saracco G; Rosina F; Torrani Cerenzia MR et al. A randomised controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis.// J Hepatol 1990; 11 (Suppl 2): 43-49.

1 88. Sata M; Tanikawa K. [Serum HCV RNA for evaluation of interferon-readministration to the former non responders in chronic hepatitis C].// Nippon-Rinsho. 1994 Jul; 52(7): 1804-9.

1 89. Schirren CA; Zachoval R; Schirren CG. A role for chronic hepatitis C virus infection in a patient with cutaneous vasculitis, cryoglobulinemia, and chronic liver disease. Effective therapy with interferon-alpha.// Dig Dis Sci. 1995 Jun; 40(6): 1221-5.

1 90. Schvarcz R; Yun ZB; Sonnerborg A; Weiland O. Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone.// J Med Virol. 1995 May; 46(1): 43-7.

1 91. Scotto G; Ferrara S; Mangano A et al.. Treatment with ribavirin+alpha interferon in HCV chronic active hepatitis non-responders to interferon alone: preliminary results.// J Chemother.1995 Feb;7(1):58-61.

1 92. Senturk A. UDCA, alone or in combination with interferon alpha in the management of chronic HCV infection./ 5th UEGW, Paris, 1996, P 25 0641.

1 93. Serfaty L; Giral P; Loria A et al. Factors predictive of the response to interferon in patients with chronic hepatitis C.// J Hepatol 1994; 21: 12-7.

1 94. Shimizu YK; Yoshikura H Multicycle infection of hepatitis C virus in cell culture and inhibition by alpha and beta interferons.// J Virol. 1994 Dec; 68(12): 8406-8.

1 95. Simmonds P; McOmish F; Yap PL et al. Sequence variability in the 5' non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity.// J Gen Virol 1993; 74:661-68.

1 96. Stokes P; Lopez WC; Balart LA. Effects of short-term corticosteroid therapy in patients with chronic non-A, non-B hepatitis.// Gastroenerology 1983; 92: 1783 (Abstr.).

1 97. Streuli M; Nagata S; Weissmann C. At least three human type interferons: structure of alpha2.// Science 1980, 209:1343-7.

1 98. Takanizava A; Mori C; Fuke I et al. Structure and organization of the hepatitis C virus genome isolated from human carriers.// Journal of Virology 1991; 65: 1105-13.

1 99. Terada M; Baba T; Ota M. [Interferon treatment for chronic hepatitis C-assessment of 3 regimens in patients received more than 500MU interferon treatment and their effect predictive factors for interferon treatment using multivariate analysis with the logistic regression model].// Nippon Shokakibyo Gakkai Zasshi. 1995 Jan; 92(1): 56-61.

200. Terada M; Ikegami F.[Interferon treatment of chronic hepatitis C-assessment of predictive factors to the effect of interferon treatment using multivariate analysis with the logistic regression model]. // Nippon Rinsho. 1994 Jul; 52(7): 1774-7.

20 1. Teuber G; Dienes HP; Meyer zum Buschenfelde KH. [Re-treatment with interferon-alpha in chronic hepatitis B and C virus infection].Interferon-alpha-Retherapie der chronischen Hepatitis-B- und -C-Virusinfektion.// Z Gastroenterol. 1995 Feb; 33(2): 94-8.

202. Thomas HC. Chronic Hepatitis C. The role of interferons in chronic viral hepatitis.// Consultant Series 1995 (4); N2: 31-2..

203. Thomas HC; Waters JA. Future approaches to treatment of chronic hepatitis B and hepatitis C virus infection.// J Viral Hep, 4, Suppl 2, 1997. pp 92-97.

204. Tine F; Margin S; Craxi A et al. Interferon for non-A,non-B chronic hepatitis. A meta-analysis of randomised clinical trials.// J Hepatol 1991; 13:192-9.

205. Todros L; Touscoz G. D'Urso N et al. Hepatitis C related chronic liver disease with autoantibodies to liver kidney microsomes (LKM).// Journal of Hepatology 1991; 13: 128-31.

206. Tong MJ; Hwang SJ; Lefkowitz M et al. Correlation of serum HCV RNA and alanine aminotransferase levels in chronic hepatitis C patients during treatment with ribavirin.// J Gastroenterol Hepatol.1994 Nov-Dec; 9(6):587-91.

207. Toy JL. The interferons.// Clin Exp Immunol 1983, 54,1-13.

208. Toyoda H; Nakano S; Takeda I. Retreatment of chronic hepatitis C with interferon Comment in: Am J Gastroenterol 1994 Sep;89(9):1424-6.// Am J Gastroenterol. 1994 Sep; 89(9): 1453-7.

209. Tran A; Quaranta JF; Benzaken S et al. High prevalence of thyroid autoantibodies in a prospective series of patients with CH-C before interferon therapy.// Hepatology, 1993, 18,253-7.

210. Trande P. Hepatitis C virus positive CAH: A randomised, controlled trial of IFN+ colchicine./ 5th UEGW, Paris, 1996, P 25 0646.

211. Trotta PP. Summary of pre-clinical data:/ Interferon-alpha2: Pre-clinical and clinical evaluation. Boston. Martinus Nijhoff Publishers, 1985,14-27.

212. Tsubota A; Chayama K; Arase Y et al. Factors useful in predicting the response to interferon therapy in chronic hepatitis C.// J Gastroenterol Hepatol 1993;8: 535-39.

213. Tsutsumi M; Takada A; Sawada M. Efficacy of combination therapy with interferon and AZT in chronic type C hepatitis: a pilot study.// J Gastroenterol. 1995 Aug; 30(4): 485-92.

214. Van Thiel DH; Gavaler GS; Wright HI et al. Responses to alfa interferon therapy are influenced by the iron content of liver (abstract).// Gastroenterology 1992; A904.

215. Van Thiel DH; Friedlander L; Molloy PJ . Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness.// Eur J Gastroenterol Hepatol.1995 Feb; 7(2):165-8.

216. Watanabe S; Ito T; Shirai M . Electron microscopic studies of peripheral blood mononuclear cells in chronic type C hepatitis treated with interferon-alpha.// Ultrastruct Pathol. 1995 Jan-Feb; 19(1): 1-8. 217. Weiland O; Schvarcz R; Wejstal R et al. Therapy of post-transfusion non-A, non-B hepatitis with interferon-alpha2b: Swedish experience.// J Hepatol 1990; 11 (Suppl 2):57-62.

218. Wright TL; Combs C; Kim M. Interferon-alpha therapy for hepatitis C virus infection after liver transplantation.// Hepatology. 1994 Oct; 20(4 Pt 1): 773-9.

219. Yamabe H; Johnson RJ; Gretch DR . Membranoproliferative glomerulonephritis associated with hepatitis C virus infection responsive to interferon-alpha.// Am J Kidney Dis. 1995 Jan; 25(1): 67-9. 220. Yamada M; Kakumi S; Yoshioka K et. al. Hepatitis C Virus genotypes are not responsible for development of Serious Liver Disease.// Dig Dis Sc, 39,2:234-39.

22 1. Yano M. [The indication and the evaluation of IFN treatment of chronic hepatitis C].// Nippon Rinsho. 1994 Jul; 52(7): 1778-83.

222. Yokosuka O; Hosoda K; Omata M.[Histological assessment of the liver long after interferon treatment in patients with chronic type C hepatitis].// Nippon-Rinsho. 1994 Jul; 52(7): 1841-6.

223. Yoshikawa M; Fukui H; Kojima H . Interferon treatment of chronic hepatitis C in patients with hemophilia or von Willebrand's disease in Japan.// J Gastroenterol. 1995 Jun; 30(3): 367-71.

224. Yoshioka K; Kakumu S; Wakita T et al. Detection of hepatitis C virus by PCR and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus.// Hepatology 1992; 16:293-99.

225. Yuasa T. The particle size of hepatitis C virus estimated through filtration through microporus regenerated cellulose fibre.// J Gen Virol 1991; 72: 2021-24.

226. Zonaro A; Ravaggi A; Puoti M et al. Differential pattern of sequence heterogeneity in the hepatitis C virus E1 and E2/NS1 protein.// J.Hepatol. 1994 Nov; 21(5): 858-65.